粤万年青公告称，本次询价转让的出让方广东金欧健康科技有限公司为公司控股股东。本次询价转 让的出让方广东侨银房地产开发有限公司为公司持股5%以上的股东，同时也是公司控股股东、实际控 制人之一致行动人。 出让方委托东吴证券组织实施公司首发前股东询价转让。 粤万年青2月3日收盘价为20.48元，以此计算，出让方套现金额约为1.6亿元。 粤万年青1月21日发布的2025年度业绩预告显示，预计2025年归属于上市公司股东的净利润亏损 200.00万元至400.00万元，扣除非经常性损益后的净利润亏损1,500.00万元至2,000.00万元。 2025年10月23日，粤万年青发布关于控股股东、实际控制人的一致行动人减持股份变动触及1%暨 减持计划实施完毕的公告。公告显示，银康管理2025年7月30日至2025年10月22日减持股数共计480万 股。经计算，银康管理套现金额为7444.8万元。 中国经济网北京2月4日讯 粤万年青(301111.SZ)昨日发布股东询价转让计划书。本次拟参与询价转 让的股东为广东金欧健康科技有限公司、广东侨银房地产开发有限公司；出让方拟转让股份的总数为 8,000,000股，占公司总股本的比 ...

Industry Overview - The "Special Regulations on the Registration Management of Traditional Chinese Medicine" is set to reshape the Chinese medicine industry, with a deadline of July 1, 2026, for compliance [1] - The regulation mandates that any traditional Chinese medicine (TCM) with unclear safety information in its instructions will not be re-registered after three years from its implementation on July 1, 2023 [1] Safety and Quality Concerns - Concerns have been raised about the safety of TCM; however, data shows that TCM accounts for only 12% of adverse drug reactions, compared to 81% for chemical drugs, indicating relative safety [2] - The core purpose of the new regulation is to enhance the safety information in TCM product instructions, promoting high-quality development in the industry [2] Company Responses - Leading companies like Yiling Pharmaceutical and Rongchang Pharmaceutical have proactively updated their product instructions to comply with the new regulations, ensuring clear statements on contraindications, adverse reactions, and precautions [3] - Yiling Pharmaceutical has 17 patented TCM products that have been revised according to regulatory requirements, while Rongchang Pharmaceutical has simplified instructions for better consumer understanding [3] Industry Transformation - The industry is at a crossroads, facing short-term compliance pressures while needing to balance innovation and regulation in the long term [4] - The government encourages high-quality development and innovation in TCM, suggesting that products with clear evidence of safety and efficacy will gain a competitive edge in the market [4] - Although the policy changes may cause short-term challenges, they are expected to lead to healthier industry development by eliminating outdated practices and improving product quality [4]

Group 1 - The A-share annual report disclosure for 2025 has commenced, with Chip导科技 being the first to release its report, showing a revenue of 394 million yuan, an 11.52% year-on-year increase, and a net profit of 106 million yuan, a 4.91% decrease [1] -沃华医药 reported a revenue of approximately 817 million yuan, a 6.96% year-on-year increase, and a net profit of about 95.71 million yuan, a 162.93% year-on-year increase, focusing on proprietary Chinese medicine products [2] - 指南针 achieved a revenue of approximately 2.146 billion yuan, a 40.39% year-on-year increase, and a net profit of about 228 million yuan, an 118.74% year-on-year increase [2] Group 2 - A total of 3,056 A-share companies have disclosed their 2025 performance forecasts, with 1,095 companies expected to report positive results, indicating significant performance differentiation [3] - Among the companies, 678 are expected to achieve a net profit growth of over 10%, and 231 companies are projected to exceed 100% growth, with some companies like 宁波富邦 and 广东明珠 expecting over 1,000% growth [3] - 619 companies are expected to have a net profit exceeding 100 million yuan, with 136 companies projected to exceed 1 billion yuan, including major players like 紫金矿业 and 中国神华 [3] Group 3 - The non-ferrous metals, automotive, chemical, and semiconductor industries are showing signs of recovery, with leading companies performing exceptionally well [4] - In the non-ferrous metals sector, gold mining companies are particularly strong, with 西部黄金 expecting a net profit of 425 to 490 million yuan, a year-on-year increase of 46.78% to 69.23% [4] - The semiconductor industry is benefiting from high order volumes and capacity utilization rates, indicating a positive outlook for the sector [4] Group 4 - 芯原股份 reported a significant increase in new orders, with a total of 5.96 billion yuan in new orders for 2025, a 103.41% year-on-year increase, and a substantial backlog of orders expected to enhance future profitability [5] - The company noted that over 73% of its new orders are related to AI computing, with over 50% in data processing, indicating a strong focus on these growth areas [5] - Following the performance forecasts, many companies have attracted institutional research interest, focusing on order volumes, production progress, and industry trends [5] Group 5 - 东芯股份 indicated that niche memory product prices are rising due to supply constraints caused by industry cycles, leading to a positive operational outlook [6] - 中集集团 expects a significant decline in container manufacturing performance for 2025 due to high base effects from 2024, but maintains a long-term positive outlook on container demand linked to global trade growth [7]

（来源：劳动午报） 转自：劳动午报 近段时间，有关"大批中成药将被淘汰"的话题登上热搜，引发消费者关注。根据监管部门要求，经过3 年缓冲期后，2026年7月1日起，中成药说明书中禁忌、不良反应、注意事项仍标注"尚不明确"的，再注 册申请将依法不予通过。这对中成药标准化提出更高要求，既是对百姓用药安全的守护，也是推动中药 行业高质量发展的重要举措。 安全是用药的"生命线"。长期以来，部分中成药的禁忌、不良反应等核心信息标注模糊，让不少患者心 中"打鼓"，既削弱公众对中医药的信任，也不利于中医药的传承与发展。 监管部门这一要求，将让中成药说明书更清晰可查、有据可依，为医生辨证用药提供科学指引，减少脱 离证候的"经验性用药"，也让老百姓明晰用药禁忌与风险，提升安全用药意识。 相关要求更强化了企业对药品安全与疗效的主体责任，倒逼企业补齐安全数据短板。唯有经得起科学审 视、市场检验，中药企业方能在变革中站稳脚跟。为此，企业需主动梳理品种，加强上市后研究，及时 修订说明书，切实守牢药品安全底线。 监管的新要求不是行业发展的"寒冬"，而是提质增效的"东风"。新规对药品说明书设置了刚性门槛，终 结了中成药批准文号"只进不出" ...

相关要求更强化了企业对药品安全与疗效的主体责任，倒逼企业补齐安全数据短板。唯有经得起科学审 视、市场检验，中药企业方能在变革中站稳脚跟。为此，企业需主动梳理品种，加强上市后研究，及时 修订说明书，切实守牢药品安全底线。 监管的新要求不是行业发展的"寒冬"，而是提质增效的"东风"。新规对药品说明书设置了刚性门槛，终 结了中成药批准文号"只进不出"的局面，淘汰安全风险不明的品种，以良性竞争倒逼产业从"数量扩 张"向"质量优先"转型。 中成药的规范化，不是单一环节的整治，而是全产业链的系统性重塑。从药品说明书修订，到价格规 范，再到饮片炮制标准完善，一系列监管举措形成合力，将推动中医药走向科学实证。这道"硬门槛"， 既守护百姓用药安全，激活行业发展动能，也将助力中医药行业更好服务全民健康。 近段时间，有关"大批中成药将被淘汰"的话题登上热搜，引发消费者关注。根据监管部门要求，经过3 年缓冲期后，2026年7月1日起，中成药说明书中禁忌、不良反应、注意事项仍标注"尚不明确"的，再注 册申请将依法不予通过。这对中成药标准化提出更高要求，既是对百姓用药安全的守护，也是推动中药 行业高质量发展的重要举措。 安全是用药的"生 ...

随着2026年7月1日《中药注册管理专门规定》第七十五条落地最后窗口期的临近，"大批中成药将退出市场"的相关话题近日引发广泛关注。真实情况是 否如此？家中常备中成药还安全吗？一起来看。 问：大批中成药真的将退出市场吗？ 答：不会出现"大批集中退市"的情形，而是不合规品种有序退出。此次政策针对的是药品再注册环节，即批准文号到期后需重新申请的中成药，并非直 接淘汰现有在售产品。 另一方面，第四批中成药集采已启动，首次纳入OTC产品和部分独家品种，参考前三批集采，中成药平均降幅可达40％以上，将进一步拉低常用药价 格。对于疗效确切、数据齐全的优质中成药，虽企业合规成本有所上升，但监管层明确"优质优价"导向，价格会保持稳定，不会盲目上涨，群众用药负 担整体将有所减轻。 答：已上市产品可正常使用。此次政策核心是补齐说明书安全信息短板，而非否定中成药的临床价值。 首先，政策针对的是药品再注册环节，即药品批准文号到期后重新申请时需符合新标准，目前家中已有的库存、市面上正在销售的中成药，均为合法合 规产品，不受直接影响。 其次，一些常用中成药龙头企业已提前布局，投入资金补充安全评价数据，可顺利完成说明书修订。专家提醒，后续部 ...

Core Viewpoint - Recent regulatory requirements for traditional Chinese medicine (TCM) aim to enhance the safety and clarity of drug information, addressing consumer concerns about the potential elimination of many TCM products [1][2] Group 1: Regulatory Changes - Starting from July 1, 2026, TCM products with unclear contraindications, adverse reactions, and precautions will not be approved for re-registration, raising the standards for TCM safety [1] - The new regulations will end the previous system where TCM approvals were only additive, promoting a competitive environment that prioritizes quality over quantity [2] Group 2: Industry Impact - The requirement for clearer labeling will provide scientific guidance for doctors and improve public awareness of medication risks, thereby enhancing the overall safety of TCM usage [1] - The regulatory changes are expected to drive a systemic transformation across the entire TCM industry, from drug labeling to pricing and production standards, fostering a shift towards evidence-based practices [2] Group 3: Corporate Responsibility - Companies are now compelled to take greater responsibility for drug safety and efficacy, necessitating the improvement of safety data and the revision of product information [1] - The emphasis on quality and safety will encourage TCM enterprises to strengthen post-market research and ensure compliance with updated standards [1][2]

证券日报网讯1月29日，三力制药（603439）在互动平台回答投资者提问时表示，公司高度关注中成药 行业相关监管政策调整，始终严格按照国家药品监管要求开展生产经营及产品研发工作。 ...

Core Viewpoint - The new regulations for traditional Chinese medicine (TCM) registration, referred to as the "death clause," will require that key safety information be clarified by July 1, 2026, or the products will face delisting. However, many industry insiders view this as an opportunity for the industry to eliminate "zombie approvals" that are no longer commercially viable [1][2][4]. Group 1: Regulatory Changes - The "New Regulations for TCM Registration" will take effect on July 1, 2026, mandating that any TCM product with unclear safety information will not be re-registered [2][3]. - Most of the TCM products likely to be eliminated are considered "zombie approvals," which are low-value, highly homogeneous products with minimal or zero market sales [2][4]. - The cost for updating safety information for TCM products ranges from thousands to tens of thousands of yuan, with an additional application fee of 9,600 yuan per approval [3][6]. Group 2: Industry Response - Industry experts believe that the impact of the new regulations on the overall sales volume of TCM will be minimal, as many products are already in excess supply [4][6]. - Companies are expected to take advantage of the three-year buffer period to either update their products or voluntarily abandon non-core approvals [10][11]. - The time frame for compliance is seen as generous, allowing companies ample opportunity to meet the new requirements without significant financial strain [8][10]. Group 3: Market Dynamics - The upcoming adjustments to the national essential drug list and the TCM centralized procurement process are viewed as more pressing concerns for the industry than the new registration regulations [10][11]. - The centralized procurement process, set to take place in November 2025, will involve 90 products and a market scale of over 45 billion yuan, raising concerns about future pricing and competition [11][12]. - The adjustment of the essential drug list is anticipated to be a critical window for TCM companies, with significant implications for core product viability and profitability [12].

药企应当如何应对挑战？邓勇建议，药企应优先梳理主要品种，统筹开展真实世界研究、文献挖掘与必 要毒理试验，及时修订说明书，并建立健全的药物警戒体系，确保药品安全、有效并符合法规要求。同 时，主动评估并注销低价值批准文号，将资源集中于真正服务临床需求的优质产品。 "许多中成药源于传统验方的加减方剂，且成分复杂。禁忌、不良反应、注意事项3项内容是当前中成药 说明书中普遍薄弱的环节。"中国中药协会合理用药专委会常务副主任委员康震认为，要客观认识中药 与西药在治疗逻辑上存在的本质差异：西药强调精准适应症，中成药的疗效高度依赖辨证论治。如果辨 证正确、用药得当，不良反应自然会减少；药性再优，如果用错证型、配伍失当、剂量失准，不良反应 则可能随之发生。 康震认为，疗效确切的经典名方制剂，临床验证充分、使用历史悠久，一般来说整体质量与信息完整性 相对可靠，风险低，说明书修订难度较小。需重点关注的是来源不清、组方随意、长期缺乏系统评价的 品种。 要让百姓真正用好中药，康震认为，除了企业必须承担起责任，医疗端也需强化辨证能力，避免脱离证 候的"经验性用药"，还要通过宣传教育提高群众对中医的理解和安全用药意识，多管齐下、相辅相成， ...